Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 1;24(5):4722.
doi: 10.3390/ijms24054722.

Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition

Sunanda Singh  1 , Hector J Gomez  1 , Shreya Thakkar  2 , Samara P Singh  3 , Ashutosh S Parihar  1
Affiliations
Review

Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition

Sunanda Singh et al. Int J Mol Sci. .

Abstract

Anti-neoplastic agents for cancer treatment utilize many different mechanisms of action and, when combined, can result in potent inhibition of cancer growth. Combination therapies can result in long-term, durable remission or even cure; however, too many times, these anti-neoplastic agents lose their efficacy due to the development of acquired drug resistance (ADR). In this review, we evaluate the scientific and medical literature that elucidate STAT3-mediated mechanisms of resistance to cancer therapeutics. Herein, we have found that at least 24 different anti-neoplastic agents-standard toxic chemotherapeutic agents, targeted kinase inhibitors, anti-hormonal agents, and monoclonal antibodies-that utilize the STAT3 signaling pathway as one mechanism of developing therapeutic resistance. Targeting STAT3, in combination with existing anti-neoplastic agents, may prove to be a successful therapeutic strategy to either prevent or even overcome ADR to standard and novel cancer therapies.

Keywords: STAT3; acquired drug resistance; chemotherapy; immune checkpoint inhibition; kinase inhibitors; monoclonal antibodies.

PubMed Disclaimer

Conflict of interest statement

Sunanda Singh, Hector J. Gomez, and Ashutosh S. Parihar are employed by and shareholders of Singh Biotechnology.

Figures

Figure 1
Figure 1
Graphical schematic depicting molecular mechanism of STAT3-mediated acquired drug resistance in response to receptor tyrosine kinases within cancer cells. Adapted from Yang et al. [144].
See this image and copyright information in PMC

References

    1. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013. - DOI - PubMed
    1. Floros K.V., Hata A.N., Faber A.C. Investigating New Mechanisms of Acquired Resistance to Targeted Therapies: If You Hit Them Harder, Do They Get Up Differently? Cancer Res. 2020;80:25–26. doi: 10.1158/0008-5472.CAN-19-3405. - DOI - PubMed
    1. Rebe C., Ghiringhelli F. STAT3, a Master Regulator of Anti-Tumor Immune Response. Cancers. 2019;11:1280. doi: 10.3390/cancers11091280. - DOI - PMC - PubMed
    1. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Jr., Kinzler K.W. Cancer genome landscapes. Science. 2013;339:1546–1558. doi: 10.1126/science.1235122. - DOI - PMC - PubMed
    1. Cao W., Liu Y., Zhang R., Zhang B., Wang T., Zhu X., Mei L., Chen H., Zhang H., Ming P., et al. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Sci. Rep. 2015;5:8477. doi: 10.1038/srep08477. - DOI - PMC - PubMed

MeSH terms